Fuzheng Yiai Decoction and Lung Cancer Treatment
Author Information
Author(s): Sun Jianfeng, Luo Danqing, Li Hui, Zhang Di, Liu Yesha, Jin Song, Guo Hong, He Chengshi, Wu Zhipeng
Primary Institution: Hospital of Chengdu University of Traditional Chinese Medicine
Hypothesis
Does Fuzheng Yiai Decoction (FZYA) reduce drug resistance in lung adenosquamous carcinoma treated with EGFR-TKIs?
Conclusion
FZYA combined with gefitinib effectively inhibits the transformation between lung cancer subtypes and reduces drug resistance.
Supporting Evidence
- FZYA combined with gefitinib showed a higher tumor control rate compared to gefitinib alone.
- High-dose FZYA treatment resulted in the greatest reduction in tumor volume and weight.
- FZYA inhibited the lineage switching between lung cancer cell subtypes.
Takeaway
This study shows that a special herbal medicine can help make lung cancer treatments work better by stopping the cancer from changing into a harder-to-treat form.
Methodology
25 nude mice were divided into groups and treated with different doses of FZYA and gefitinib, followed by tumor volume and weight measurements.
Potential Biases
Potential bias in the selection of treatment groups and the small sample size may affect the reliability of the findings.
Limitations
The study was conducted on a small sample size of mice, which may limit the generalizability of the results.
Participant Demographics
Male BALB/c nude mice, 4 weeks old.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website